P582 The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016
Han S., Kim S., Kim J., Kwon D.-H., Choi J.-S., Yoon S.-R., Yun S.-H., Kim D.-S., Bae J.-H., Choi H.-J., Sung H.-Y., Yoon S.-W.
Celltrion Healthcare Co., Ltd, Incheon, South Korea
CT-P13, a biosimilar of infliximab, has been approved by the US FDA and the European Medicines Agency. CT-P13 is offered at a lower price than the infliximab reference product (RP), therefore its use could reduce the economic burden associated with biologic therapy and increase access to treatment. This study analysed the real-world pharmacoeconomic effects of CT-P13 use in 5 European countries from 2015 to the end of the second quarter (Q2) of 2016.
Surveys were conducted by IMS Health in France, Germany, Spain, Italy and UK to evaluate market share of CT-P13. Public prices for CT-P13 and RP in France, Spain, Italy and UK were used to evaluate costs. In Germany, prices were calculated using IMS Health sales data. Total cost savings were calculated as (Number of CT-P13 vials sold) x (RP price – CT-P13 price). The number of additional patients able to access biologic therapy was calculated as (Number of assessable vials†) x (100/3.75††)/365, where † was defined as (Cost saving in each country)/(CT-P13 price in each country), and †† was the infliximab index from the WHO's Anatomical Therapeutic Chemical (ATC) classification system with defined daily dose (DDD) (i.e. ATC/DDD).
Market share of CT-P13 in the first quarter (Q1) of 2015 in France, Germany, Spain, Italy and UK was 0, 2.0, 4.4, 0.3 and 0.1%, respectively. By the end of Q2 2016 this had risen to 19.6, 25.3, 36.8, 55.2 and 72.6%, respectively (Figure 1).
From 2015 to the first half of 2016, total cost savings associated with CT-P13 use in Germany, Spain, Italy and UK were €2,791,405, 12,233,004, 9,958,223 and 7,453,488, respectively. Public prices for CT-P13 and RP were the same in France; therefore, there were no cost savings. Use of CT-P13 in place of RP could enable an additional 369, 2222, 1699, or 1138 patients per year to access biologic therapy in Germany, Spain, Italy and UK, respectively.
In 4 of the 5 European countries in this study, use of CT-P13 instead of RP led to real-world cost savings. The lower cost of CT-P13 has ensured this biosimilar has rapidly entered into use, while the market share of RP has decreased. Even in France, where the price of CT-P13 and RP is the same, use of the biosimilar has gradually increased. Competition between CT-P13 and RP may drive down costs of both. It is anticipated that as the market share of CT-P13 increases, the economic burden in each country will decrease, increasing access to biologic therapy.